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Abstract
Background: Optimal timing for initiating highly active antiretroviral therapy (HAART) in HIV-TB coinfected patients
is challenging for clinicians. We aim to evaluate the impact of different timing of HAART initiation on TB outcome
of HIV-infected adults in Taiwan.
Methods: A population-based retrospective cohort study was conducted through linking the HIV and TB registries
of Taiwan Centers for Disease Control (CDC) during 1997 to 2006. Clinical data of HIV-TB co-infected patients,
including the presence of immune reconstitution inflammatory syndrome (IRIS), was collected through medical
records review. The outcome of interest was all-cause mortality within 1 year following TB diagnosis. The Cox
proportional hazard model was used to explore the probability of death and IRIS after TB diagnosis by adjusting for
confounding factors and factors of interest. The probability of survival and TB IRIS were calculated by the
Kaplan-Meier method and compared between different HAART initiation timing groups by the log-rank test.
Results: There were 229 HIV-TB co-infected patients included for analysis and 60 cases (26.2%) died within one year.
Besides decreasing age and increasing CD4 lymphocyte count, having started HAART during TB treatment was
significantly associated with better survival (adjusted Hazard Ratio was 0.11, 95% CI 0.06–0.21). As to the timing of
HAART initiation, there was only non-significant benefit on survival among cases initiating HAART within 15 days, at
16–30 days and at 31–60 days of TB treatment than initiating after 60 days. Cases with HAART initiated after 30 days
had lower risk in developing IRIS than cases with HAART initiated earlier. Cases with IRIS had significantly higher rate
of re-hospitalization (49% vs. 4%, p < 0.001) and prolonged hospitalization (28 days vs. 18.5 days, p < 0.01).
Conclusion: The present study found that starting HAART during TB treatment is associated with better one-year
survival, although earlier initiation within 60 days of TB treatment did not show statistical differences in survival than
later initiation. Initiation of HAART within 30 days appeared to increase the risk of IRIS. Deferring HAART to 31–60
days of TB treatment might be optimal after considering the risks and benefits.
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Background
Among the 1.3 million people who died from tuberculosis
(TB) in 2012, one-quarter were also HIV-infected [1]. Al-
though highly active antiretroviral therapy (HAART) can
reduce the mortality of HIV-TB co-infected patients, HIV-
infected individuals still had a higher TB mortality rate than
HIV-uninfected individuals [2-5].
Various aspects of therapy, such as drug interactions,
overlapping toxicity and the risk of immune reconstitution
inflammatory syndrome (IRIS), make the treatment of TB
complex in HIV-infected persons. Observational studies
found that deferral of HAART in TB treatments are
associated with higher mortality [6,7]. Nevertheless, early
initiation of HAART during TB treatment is strongly asso-
ciated with the occurrence of IRIS [8,9]. Although deaths
resulting directly from TB IRIS appear to be limited, the de-
velopment of IRIS usually results in higher hospitalization
rate, interruption of TB treatment and longer time to reso-
lution [10,11].
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Results from randomized controlled trials (RCTs) pro-
vide evidences regarding the timing of HAART initiation
and treatment outcome among HIV-TB co-infected pa-
tients. The SAPiT trial in South Africa and ACTG 5221
STRIDE trial in Africa and North America both demon-
strated that early initiation of HAART (within 2–4
weeks after TB treatment) can reduce AIDS events and
deaths in persons with CD4+ lymphocyte counts ≤ 50
cells/mm3, though no significant benefits were observed
in patients with higher CD4+ lymphocyte counts
[12,13]. CAMELIA trial in Cambodia showed that early
initiation of HAART can reduce mortality in patients
with CD4+ lymphocyte counts ≤ 200 cells/mm3 [14].
TIME study in Thailand, on the other hand, found that
early initiation of HAART was not associated with sur-
vival advantages [15]. Because the study design of RCTs
usually excluded patients with abnormal liver function,
the results might not be generalizable to areas with high
HBV and HCV prevalence such as Taiwan [16]. In
addition, because the majority of the participants in the
trials were from resource constrained countries, the re-
sults might not be applicable to countries with better
resources.
Taiwan, with moderate TB burden (2011 prevalence
was 54.5 per 100,000 population ) and low HIV preva-
lence (0.16% in 2011), has good health infrastructure
and public health system to implement national HIV
and TB programs [17,18]. There were 12,634 new TB
cases in 2011 and around 22,000 persons living with
HIV by the end of 2011 [19].
We conducted a retrospective cohort study of HIV-TB
co-infected patients from 1997 to 2006 through medical
records review. Clinical data collected included the date
of HAART initiation, presence of IRIS and one-year sur-
vival, stratified by CD4+ lymphocyte counts of 50 cells
/mm3. Our aim was to understand the TB outcome of
HIV-infected adults under routine programmatic condi-
tions in Taiwan and hope to contribute to the under-




Both HIV infection and tuberculosis were mandatorily re-
portable in Taiwan since 1984. Cases of HIV infection de-
tected by ELISA must be confirmed by Western blot. HIV/
AIDS infected individuals are provided with free medical
care by the government of Taiwan, including HAART,
which was introduced in 1997 [20]. Computerized National
Tuberculosis Registry was established in 1994 and physi-
cians are required to report all suspected and confirmed
TB cases within 7 days [21]. There are no parallel reporting
systems for laboratories or pharmacies.
Data collection
We linked all data prior to 2007 in the HIV and TB
registries of Taiwan CDC to identify HIV-TB co-infected
patients. Patients with HIV diagnosed before TB diagno-
sis or within 5 months after TB diagnosis were enrolled.
To assess the effect of HAART on the survival of pa-
tients with TB and to avoid biases resulted from anti-
retroviral use, we only included patients with TB
diagnosed after 1997 who were not on HAART when
TB was diagnosed for analysis. All medical and microbi-
ologic records were reviewed by physicians to obtain
clinical information which included date of diagnosis;
type of TB (pulmonary or extra-pulmonary); antiretro-
viral drugs used before and after the diagnosis of TB;
and CD4+ lymphocyte count and HIV viral load closest
to the date of TB diagnosis. For patients with significant
adverse effects from drugs or IRIS during anti-TB treat-
ment, clinical records were reviewed.
Definitions
We only included bacteriologically confirmed TB cases,
which was defined as: (1) a positive smear of acid-fast bacilli
(AFB) without culture result and disease clinically compat-
ible with TB infection; (2) a successful culture of Mycobac-
terium tuberculosis (MTB) from pulmonary or extra-
pulmonary specimens. TB was divided into pulmonary (dis-
ease localized to the lungs only) or extra-pulmonary (dis-
ease anywhere outside the lungs).
HAART was defined as combination therapy of at
least 3 antiretroviral drugs that included at least a prote-
ase inhibitor or non-nucleoside reverse transcriptase
inhibitor. The most common HAART regimen for HIV-
TB co-infected patients consisted of stavudine or
zidovudine, lamivudine and efavirenz. If patients experi-
enced adverse effects, they were shifted to a protease-
inhibitor-based ART regimen and rifampin in their
TB-treatment regimen was replaced with rifabutin [22].
Both anti-TB and HAART were self-administered by
patients.
Enrolled patients were divided into 5 groups: patients
who did not receive HAART during TB treatment; pa-
tients whose HAART was initiated within 14 days; be-
tween 15–30 days; between 31–60 days; and over 60
days from the date of starting TB treatment. IRIS was
defined as deterioration in either clinical status or la-
boratory findings following the initiation of antiretroviral
therapy in the absence of other causes.
The outcome of interest studied was all-cause mortality
within 1 year following TB diagnosis and treatment. Death
at 1 year post-TB diagnosis was determined from medical
records and verified using Taiwan’s National Death Registry.
Deaths were determined to be TB-related if two or more of
the following conditions were met: TB was listed as a cause
of death in the pathological examination report; TB was
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identified in discharge summaries as a probable cause of
death; or, patient had a positive AFB smear or culture for
Mycobacterium tuberculosis from any specimens taken
within 6 weeks prior to death.
Statistical analysis
Categorical variables were described by their absolute
counts and percentages. Numerical variables were de-
scribed by median with interquartile range at 25th and 75th
(IQR). χ2 tests and Student’s t-test were used to compare
categorical and continuous variables, respectively. The Cox
proportional hazard model was used to explore the prob-
ability of death and IRIS after TB diagnosis by adjusting for
confounding factors and factors of interest. Factor which
had p value of less than 0.15 by univariate analysis and fac-
tors of interest were included into the multivariate analysis.
The results were expressed as hazard ratios (HRs) with 95%
confidence intervals (CI). The probability of survival and
TB IRIS were calculated by the Kaplan-Meier method and
compared between different HAART initiation timing
groups by the log-rank test. All comparisons were two-
tailed with p values < 0.05 considered to be statistically sig-
nificant. Statistical analysis was performed using SAS,
version 9.3, software (SAS Institute, Cary, North Carolina,
USA).
Ethics
The study was approved by the Centers for Disease Con-
trol, Ministry of Health and Welfare, Executive Yuan,
Taiwan. To preserve patient confidentiality, only the author
or physicians working in the designated hospitals were re-
sponsible for data extraction from patients’ medical records.
Moreover, no personal identifiers were used on the data
collection form.
Results
Among the 13,013 reported HIV-infected persons in
Taiwan by the end of 2006, there were 389 patients (3.0%)
who had at least 1 episode of bacteriologically confirmed
TB occurring after 1997. Excluding 134 patients who were
already on HAART when TB was diagnosed, a total of 229
cases met the inclusion criteria for analysis (Figure 1). The
demographic data is shown in Table 1. The median CD4+
lymphocyte count at TB diagnosis was low and did not vary
with time. The 11 cases without CD4+ lymphocyte count
data had the highest mortality rate and 9 of them did not
initiate HAART. Other than being significantly older, these
patients showed no other demographic differences from
the other patients. There were 60 patients (26.2%) who died
within one year; 27 deaths (45.0%) occurred within 60 days
after TB diagnosis. Only older age and patients without
HAART during TB treatment were associated with death;
the p value was 0.002 and <0.001 respectively.
There were 45 patients who did not receive HAART
while being treated for TB. These patients were signifi-
cantly older, had higher CD4+ lymphocyte count, and
higher rate of HCV co-infections. Possible reasons for
not starting HAART included: 7 cases had CD4+
lymphocyte count ≥200 cells/mm3 (all survived); 3 cases
defaulted from TB treatment (all survived); 10 cases died
within 15 days after TB diagnosis; 8 cases had other con-
ditions (3 with abnormal liver function because of liver
cirrhosis; 2 with cancer; 1 committed suicide; 1 had se-
vere sepsis; and 1 had personal reasons; all of them
Figure 1 Flow chart showing HIV-TB co-infected individuals recruited for analysis.
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died). There was 1 case that the reason for not starting
HAART remained unknown and died at 54 days after
TB treatment. There were 4 patients whose HIV diagno-
ses were delayed for over 1 month after TB diagnosis,
and they all died. As to the other 12 cases, their medical
records did not mention HIV infection during the diag-
nosis and treatment of TB, and 7 of them died.
Further analysis of the 218 patients with CD4+ lympho-
cyte counts available, the highest mortality rate occurred
among the 36 patients who never initiated HAART (Table 2).
The next highest mortality rate was observed among the 19
patients whose HAART was delayed for at least 60 days
(26.3%), followed by patients in whom HAART began
within 15 days (17.3%), in 16–30 days (14.7%) and 31–60
days (0%). There were 39 TB-related deaths (75.0%), and
their mortality rate trend was similar to that of all deaths.
Cases with HCV co-infection had significantly lower chance
to initiate HAART during TB treatment than cases without
Table 1 Characteristics of 229 HIV-infected patients co-infected with tuberculosis
Died (n = 60, 26.2%) Survived (n = 169) Total (n = 229)
TB diagnosis year
1997–2000 12 (20.3%) 47 (79.7%) 59 {25.8%}
2001–2003 19 (29.2%) 46 (70.8%) 65 {28.4%}
2004–2006 29 (27.6%) 76 (72.4%) 105 {45.9%}
Age (yrs) at first TB diagnosis, median [IQR]$ 42.1 [33.3-53.5] 36.8 [32.4-43.6] 37.5 [32.5-47.1]
Male 55 (25.6%) 160 (74.4%) 215 {93.9%}
Female 5 (35.7%) 9 (64.3%) 14 {6.1%}
HIV transmission category
MSM 18 (20.0%) 72 (80.0%) 90 {39.3%}
Heterosexual contacts 33 (39.7%) 78 (70.3%) 111 {48.5%}
IDUs 4 (19.1%) 17 (81.0%) 21 {9.2%}
Other/undefined 5 (71.4%) 2 (28.6%) 7 {3.1%}
CD4 count (/mm3) at TB diagnosis, median [IQR] 22 [7-85] 43 [20-117] 40 [17-107]
≤50 32 (25.2%) 95 (74.8%) 127 {55.5%}
51–100 9 (25.0%) 27 (75.0%) 36 {15.7%}
101–200 8 (33.3%) 16 (66.7%) 24 {10.5%}
≥200 3 (9.7%) 28 (90.3%) 31 {13.5%}
No data 8 (72.7%) 3 (27.3%) 11 {4.8%}
Localization of tuberculosis
Pulmonary 22 (26.8%) 60 (73.2%) 82 {35.8%}
PTB+ extra-pulmonary 37 (28.2%) 94 (71.8%) 131 {57.2%}
Extra-pulmonary 1 (6.3%) 15 (93.8%) 20 {7.0%}
Laboratory findings
Positive AFS smear 46 [76.7%] 127 [75.2%] 173 {75.6%}
Positive MTB culture 49 [81.7%] 139 [82.3%] 188 {82.1%}
HAART during anti-TB treatment$
No 30 (66.7%) 15 (33.3%) 45 {19.7%}
Yes 30 (16.3%) 154 (83.7%) 184 {80.3%}
IRIS* 5 (8.8%) 52 (91.2%) 57 {31.0%}*
HBV (+)# 7 [11.7%] 29 [17.2%] 36 {15.7%}
HCV (+)# 5 [8.3%] 22 [13.0%] 27 {11.8%}
Data are presented as n (% of the category) unless otherwise indicated. {%} indicated as the proportion of the total reported cases. [%] indicated as the
proportion in the subgroup.
Abbreviations: IQR interquartile range, PTB pulmonary tuberculosis. AFS acid-fast stain, MTB Mycobacterium tuberculosis, MSM men who had sex with men, IDUs
injecting drug users, HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome, HBV hepatitis B virus infection, HCV hepatitis
C virus infection.
*Only cases started HAART were counted as denominator.
#Only 156 and 144 patients had available HBV and HCV examination results respectively.
$ p < 0.01.
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or had unknown HCV status (p < 0.01); HBV co-infection
did not show such findings. One third of the patients devel-
oped IRIS after initiation of HAART. The median duration
from HAART initiation to the development of IRS was 10
days (range 1–37 days). The incidence of IRIS was signifi-
cantly higher in patient who started HAART within 30 days
compared with those who started after 30 days (36.8% vs.
10.5%, p < 0.05). The mortality rate was lower among pa-
tients with IRIS than those without IRIS (8.8% vs. 19.2%, p
= 0.08). Five deaths among patients with IRIS all had
HAART initiated within 30 days after TB treatment. Pa-
tients who developed IRIS had significantly higher rate of
re-hospitalization than those without IRIS (49% vs. 4%, p <
0.001). Patients who developed IRIS also had prolonged
mean hospitalization duration than those without (28 days
vs. 18.5 days, p < 0.01).
Multivariate analysis of factors associated with all-cause
mortality among cases with different timing of HAART ini-
tiation was conducted (see Table 3). Increasing CD4+
lymphocyte counts and decreasing age were associated with
favorable outcomes. Having started HAART during TB
treatment was associated with significantly better survival
and the aHR was 0.11 (95% CI 0.06–0.21); stratifying the
cases into CD4+ lymphocyte counts >50 cells/mm3 and
≤50 cells/mm3 showed similar results, with aHR of 0.08
(95% CI 0.03-0.17) and 0.12 (95% CI 0.04-0.37), respectively
(data not shown). Among patients with CD4+ lymphocyte
counts ≤50 cells/mm3, no matter when HAART was
started, even within 15 days, there was a survival benefit
compared to those who never started HAART (see
Additional file 1). Use HAART initiated after 60 days as ref-
erence, there were no statistical differences in survival com-
pared to patients whose HAART was initiated at 0–15 days
and 16–30 days. Further stratify with CD4+ lymphocyte
counts 50 cells/mm3 showed the same results (see
Additional file 1). The cumulative survival probabilities
after TB diagnosis of the 4 groups with different HAART
initiation timing is shown in Figure 2 (p = 0.18, log-rank
test). Cases initiated HAART after 30 days had significantly
lower risk in developing IRIS than those who had HAART
initiated earlier; the HR was 4.10 (95% CI 1.48–11.33, data
not shown). Multivariate analysis of factors associated with
Table 2 Characteristics of the 218 HIV-TB co-infected patients divided by initiation timing of HAART*











Age (yrs) at first TB diagnosis, median [IQR] 38.8 [32.0–49.6] 36.8 [31.8–43.6] 35.5 [31.2–46.7] 36.6 [33.7–45.1] 40.4 [29.5–61.3]
Male 31 (86.1%) 107 (97.3%) 33 (97.1%) 18 (94.7%) 17 (89.5%)
Female 5 (13.9%) 3 (2.7%) 1 (2.9%) 1 (5.3%) 2 (10.5%)
CD4 count(/mm3) at TB diagnosis, median [IQR]$ 69 [17–370] 37 [16–87] 34 [14–62] 68 [23–134] 36 [17–94]
≤50 14 (38.9%) 68 (62.4%) 26 (74.3%) 8 (42.15%) 11 (57.9%)
51–100 7 (19.4%) 18 (16.4%) 2 (5.9%) 5 (26.3%) 4 (21.1%)
101–200 5 (13.9%) 11 (10.1%) 3 (8.6%) 4 (21.1%) 1 (5.3%)
≥200 10 (30.8%) 13 (11.9%) 3 (8.6%) 2 (10.5%) 3 (15.8%)
Localization of tuberculosis
Pulmonary 16 (44.4%) 31 (28.5%) 15 (42.9%) 6 (31.6%) 7 (36.8%)
PTB+ extra-pulmonary 19 (52.8%) 72 (65.5%) 19 (55.9%) 6 (31.6%) 12 (63.2%)
Extra-pulmonary 1 (2.8%) 7 (6.4%) 0 7 (36.8%) 0
Laboratory findings
Positive AFS smear ± positive MTB Culture 27 (75.0%) 85 (78.0%) 29 (82.9%) 13 (68.4%) 12 (63.2%)
Positive MTB culture only 9(25.0%) 25(22.7%) 5(14.7%) 6(31.6%) 7(36.8%)
HBV(+)#$ 6(16.7%) 22(20.2%) 1(2.9%) 4(21.1%) 3(15.8%)
HCV(+)#$ 9(25.0%) 11(10.1%) 3(8.6%) 1(5.3%) 1(5.3%)
IRIS$ – 41(37.3%) 12(35.3%) 2(10.5%) 2(10.5%)
Death$ 23(63.9%) 19(17.3%) 5(14.7%) 0 5(26.3%)
TB-related death$ 19(52.8%) 15(13.6%) 2(5.9%) 0 3(15.8%)
Data are presented as n (% of the category) unless otherwise indicated.
Abbreviations: IQR interquartile range, PTB pulmonary tuberculosis. AFS acid-fast stain, MTB Mycobacterium tuberculosis, IRIS Immune reconstitution inflammatory
syndrome, HBV hepatitis B virus infection, HCV hepatitis C virus infection.
*Only included cases with available CD4+ lymphocyte count.
#Only 153 and 141 patients had available HBV and HCV examination results respectively.
$ p <0.01.
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IRIS occurrence among cases with different timing of
HAART initiation is shown in Table 4 and Figure 3.
Discussion
Our study showed that patients who had HAART initi-
ated during anti-TB treatment had better one-year sur-
vival than those who did not. The benefit was significant
for both patients with CD4+ lymphocyte counts >50
cells/mm3 and ≤50 cells/mm3. There were no statistical
differences in one-year survival between patients who
had HAART initiated within 15–60 days of TB treat-
ment and those who had delayed HAART initiation to
after 60 days. Patients with HAART initiated after 30
days of TB treatment had lower risk of IRIS than those
who had HAART initiated within 30 days.
HAART during anti-TB treatment was the most im-
portant determinant of one-year survival among HIV-TB
co-infected patients, especially in patients with CD4+











Age at TB diagnosis (per 5-year increase) 1.14 (1.03-1.27) 1.12 (1.01-1.25) 1.13 (0.97-1.32)
CD4 count at TB diagnosis (per 50-cell increase) 0.94 (0.83-1.06) 0.81 (0.71-0.92) 0.79 (0.60-1.05)
IRIS 57 5 (8.8%) 0.26 (0.10-0.65) 0.36 (0.14-0.97) 0.36 (0.13-0.95)
HAART initiation timing during anti-TB therapy
No HAART 36 23 (63.9%) 1 1
0–15 days 110 19 (17.3%) 0.17 (0.09-0.31) 0.14 (0.07-0.27) 0.97 (0.34-2.70)
16–30 days 34 5 (14.7%) 0.14 (0.05-0.36) 0.10 (0.04-0.28) 0.69 (0.19-2.49)
31–60 days 19 0 (0%) – – –
>60 days 19 5 (26.3%) 0.25 (0.10-0.67) 0.14 (0.05-0.39) 1
Abbreviations: HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
*Only enrolled cases with available CD4+ lymphocyte count. HBV co-infection, HCV co-infection and TB location were analyzed initially but the p value was greater
than 0.15 and was not included for multivariate analysis and not shown in the table.
$ Adjusted for age at TB diagnosis, CD4 + lymphocyte count, IRIS and HAART initiation timing (use no HAART as reference).
#Excluded cases who did not start HAART during TB treatment and adjusted for age at TB diagnosis, CD4+ lymphocyte count, IRIS and HAART initiation timing
(use after 60 day as reference).
Figure 2 Kaplan-Meier plot of survival after TB diagnosis stratified by the timing of HAART initiation. Use HAART at 31–60 days as
reference, the p value by log-rank test was 0.03 for HAART after 60 days; p value by log-rank test was both >0.05 for HAART at 0–15 days and at
16–30 days.
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lymphocyte counts ≤50 cells/mm3. HAART can improve
the patients’ immune status and avoid excess deaths be-
cause of other opportunistic infections [23,24]. Our study
found one third of the deaths were not TB-related. There
were 4 patients who died of Pneumocystis jiroveci pneumo-
nia, 2 hepatic failures, 2 sepsis, 2 diabetes mellitus with
renal failure, 2 hematologic cancers and 1 suicide. The pro-
portion of non-TB deaths was higher among patients with-
out HAART, compared with those who started HAART
(11.1% vs. 4.9%, p = 0.15), though the difference is not sta-
tistically significant. Unfortunately, we found that some
patients missed the chance to start HAART early because
of unknown HIV status during anti-TB treatment. There
were 16 cases that did not disclose their HIV status and the
attending physicians did not recognize or had delayed rec-
ognition of the patient’s HIV status during TB treatment.
WHO recommended offering HIV testing to all TB pa-
tients. The estimated rate of HIV testing reached 46% of
notified TB cases in 2012 globally, but implementation in
the Western Pacific region is still low, reaching 34% only
[1]. HIV testing rate among TB patients is only 28.8% in
Taiwan [25]. Furthermore, although HAART is freely











Age at TB diagnosis (per 5-year increase) 0.99 (0.97-1.01) 0.99 (0.97-1.02) 0.99 (0.97-1.02)
CD4 count at TB diagnosis (per 50-cell increase) 0.95 (0.81-1.11) 0.97 (0.83-1.13) 0.97 (0.83-1.13)
HAART initiation timing during anti-TB therapy
0–15 days 110 41 (71.9%) 1 1 4.24 (1.02-19.5)
16–30 days 34 12 (21.1%) 0.98 (0.51-1.86) 0.96 (0.50-1.84) 4.08 (0.91-18.3)
31–60 days 19 2 (3.5%) 0.23 (0.06-0.96) 0.24 (0.06-0.98) 1
>60 days 19 2 (3.5%) 0.26 (0.06-1.06) 0.27 (0.07-1.12) 1.14 (0.16-8.11)
Abbreviations: HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
*Only enrolled cases with available CD4+ lymphocyte count and start HAART during TB treatment. HBV co-infection, HCV co-infection and TB location were ana-
lyzed initially but the p-value was greater than 0.15 and was not included for multivariate analysis and not shown in the table.
#Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 0–15 days as reference).
$Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 31–60 days as reference).
Figure 3 Kaplan-Meier plot of TB-IRIS occurrence after HAART stratified by the timing of HAART initiation. Use HAART at 31–60 days as
reference, p value by log-rank test was 0.02 and 0.08 for HAART at 0–15 days and at 16–30 days; p value by log-rank test was 0.85 for HAART after
60 days. The p value by log-rank test between HAART after 60 days and 0–15 days was 0.02.
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available in Taiwan, there are some HIV-infected patients
who do not link into HIV-related medical care [26]. The
barrier between HIV-TB co-infected patients and medical
services is also reported in other studies [27,28]. In mid-
2013, the National TB program launch a project to have
every TB patient aged 15–49 years complete HIV test. Inte-
gration of HIV and TB services to improve HIV testing
among TB patients and overcome obstacles are important
in reducing these events.
As to the timing of HAART initiation, in 2009, WHO
recommend initiating HAART within 15–60 days after
anti-TB treatment [29]. Results from studies were incon-
sistent. Some found early initiation of HAART within 4
weeks after TB treatment can reduce mortality [12-14],
but others found the timing had no significant impact
[15,30,31]. The benefit of early HAART (within 30 days)
is contingent on increased risk and severity of IRIS ac-
companied with higher re-hospitalization rate and longer
TB treatment duration. We have similar observations
with previous studies [8,10,32]. In addition, we found
several cases had prolonged hospitalization because of
persistent positive sputum smear. Although we cannot
demonstrate the time to sputum conversion had differed
between cases with and without IRIS because of the
retrospective study design, prolonged hospitalization
hints at this possibility. There were no studies focused
on the period of infectiousness following TB IRIS. More
research is needed for this important topic, because this
may lead to further transmission in the community.
We found that initiating HAART between 31–60 days
after TB treatment may be a feasible way to balance the
risks and benefits. Our results showed that cases in this
group had good survival and the survival probabilities was
not different compared with cases that started HAART be-
tween 16–30 days, even if the cases had CD4+ lymphocyte
counts of ≤50 cells/mm3. One retrospective chart review
study in Durban had the same observation [30]. This is dif-
ferent from the results of Rwanda’s retrospective cohort
analysis, where the authors, using marginal structural
models, found that HAART initiation at day 15, instead of
later times, was protective against death [33]. We noticed
that 11% of our patients had HAART initiation deferred to
between 31–60 days after TB treatment. In the SAPiT trial,
the study protocol design allowed HAART initiation timing
in early-HAART arm to be at the discretion of the physi-
cians. There were 33 cases (15% of original assignment)
started HAART after 4 weeks [13]. Although there were no
further analyses of the outcome for these patients, it dem-
onstrates that some patients cannot have HAART initiated
within 4 weeks of anti-TB treatment. If the deferral of
HAART to 30 days after TB treatment did not increase
mortality and can also reduce the incidence of IRIS, it
would offer better flexibility for clinical judgment. This tim-
ing has not been discussed in previous RCTs. This finding
is distinct from, yet complementary to, the results of previ-
ous RCTs and need more research to prove this hypothesis.
Our results showed that HIV/HCV co-infected pa-
tients had higher chance to have HAART withheld dur-
ing TB treatment. Anti-TB drug-induced hepatotoxicity
is the most common physician-determined reason to
defer HAART initiation [34]. The median time to the
development of hepatotoxicity is 14 days after TB treat-
ment, thus the initiation of HAART would also be de-
layed or suspended because of abnormal liver function
[35,36]. The rate of anti-TB drug-induced hepatotoxicity
is high in Taiwan [37,38], and is even higher in HIV/
HBV or HIV/HCV co-infected patients [36,39,40]. Our
study found high prevalence of HCV co-infection in
HIV-infected individuals, thus increased frequency of
liver function monitoring before HAART initiation is
necessary. Aggressive latent tuberculosis infection treat-
ment or HCV related treatment in patients with HIV/
HCV co-infection might be another option to solve the
problem.
There are some limitations in our analysis. First, this is
a retrospective study and the reason for a clinicians’
judgment as to the timing of HAART was not always
clearly recorded. Second, this is a nationwide study and
the data was collected from several hospitals. There were
approximately 40 designated hospitals providing free
HIV-related medical care in Taiwan, the majority of
which were tertiary medical centers of excellent quality
[20]. Around 82% of our patients were treated in med-
ical centers and the mortality rate was 22%; this is not
statistically different from patients who were treated in
regional hospitals, where the mortality rate was 14%.
Thus the quality of medical care did not show significant
difference. Third, the case number was small and the
distribution was uneven in our study, despite the study
was based on Taiwan’s national HIV and TB surveillance
dataset and can therefore be considered a population-
based study for this area. In addition, the Taiwan govern-
ment offers free HIV- and TB-related medical care
through its national health insurance system, patients do
not have to pay for treatment, leading to a higher per-
centage of individuals seeking HIV and TB related care.
This situation, however, may not be representative of
resource-constrained areas.
Conclusion
In conclusion, the present study support that HAART
initiated during TB treatment was associated with better
one-year survival, though initiation within 60 days of TB
treatment did not show statistical difference in survival
than later initiation. Initiation of HAART within 30 days
appeared to increase the risk of IRIS. Deferring HAART
to 31–60 days of TB treatment might be optimal after
considering the risks and benefits.
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lymphocyte count > or ≤ 50 cells/mm3.
Competing interests
There was no financial support for this study. On behalf of all authors, the
corresponding author states that there is no conflict of interest.
Authors’ contributions
CHY conceived of and designed this study and drafted the manuscript. HYC
participated in the study design and analysis. KJC, JJT, YHL and SHC
participated in the clinical data collection. KFW helped to link the datasets to
identify those patients who matched the enrollment criteria. All authors
were provided critical comments for revision and approved the final version
of the manuscript.
Acknowledgments
The author wishes to thank physicians from all of the HIV-designated hospitals
in Taiwan for participating in the study. We also acknowledge the TB-HIV officer
from Taiwan Centers for Disease Control for their help in data linkage and
collection exercises.
Author details
1Centers for Disease Control, Ministry of Health and Welfare, 5F, No.6, Linsen
S. Rd., Taipei City 100, Taiwan. 2Ph. D. program in School of Public Health,
Taipei Medical University, No. 250, 469 Wu-Hsing Street, Taipei, Taiwan.
3Department of Chest Medicine, RenAi branch of Taipei City Hospital, No. 10,
Section 4, Ran-Ai Road, Taipei, Taiwan. 4School of Medicine, College of
Medicine, Kaohsiung Medical University, No.100, Shih-Chuan 1st Road,
Kaohsiung, Taiwan. 5Division of Infectious Diseases, Department of Internal
Medicine, Kaohsiung Medical University Hospital, , No.100, Tzyou 1st Road,
Kaohsiung, Taiwan. 6Tropical Medicine Center, Kaohsiung Medical University
Hospital, School of Medicine, College of Medicine, Kaohsiung Medical
University, No.100, Tzyou 1st Road, Kaohsiung, Taiwan. 7Section of Infectious
Diseases, Department of Internal Medicine, Taichung Veterans General
Hospital, No.1650, Sec. 4, Taiwan Boulevard, Taichung, Taiwan. 8Section of
Infectious Diseases, Department of Internal Medicine, Taoyuan General
Hospital, No. 1492, Chung-Shan Road, Taoyuan, Taiwan. 9School of Public
Health, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei, Taiwan.
Received: 18 February 2014 Accepted: 30 May 2014
Published: 4 June 2014
References
1. WHO: Global tuberculosis report 2013. Geneva: World Health Organization;
2013.
2. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D,
Monkongdee P, Sitti W, Rienthong D, Siraprapasiri T, Wells CD, Tappero JW,
Varma JK: Antiretroviral therapy during tuberculosis treatment and
marked reduction in death rate of HIV-infected patients, Thailand.
Emerg Infect Dis 2007, 13:1001–1007.
3. Dheda K, Lampe FC, Johnson MA, Lipman MC: Outcome of HIV-associated
tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis
2004, 190:1670–1676.
4. Mugusi FM, Mehta S, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW:
Factors associated with mortality in HIV-infected and uninfected patients
with pulmonary tuberculosis. BMC Public Health 2009, 9:409.
5. US CDC: Mortality among patients with tuberculosis and associations
with HIV status –- United States, 1993–2008. MMWR Morb Mortal Wkly Rep
2010, 59:1509–1513.
6. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, Cervero M, Torres
R, Guijarro C, COMESEM Cohort: Effect of simultaneous use of highly
active antiretroviral therapy on survival of HIV patients with tuberculosis.
J Acquir Immune Defic Syndr 2009, 50:148–152.
7. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C,
Sattayawuthipong W, Burapat C, Kittikraisak W, Monkongdee P, Cain KP,
Wells CD, Tappero JW: HIV care and treatment factors associated with
improved survival during TB treatment in Thailand: an observational
study. BMC Infect Dis 2009, 9:42.
8. Lawn SD, Myer L, Bekker LG, Wood R: Tuberculosis-associated immune
reconstitution disease: incidence, risk factors and impact in an
antiretroviral treatment service in South Africa. AIDS 2007, 21:335–341.
9. Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B,
LaHart C, Mangura B, Weiner M, El-Sadr W: Frequency, severity and
duration of immune reconstitution events in HIV-related tuberculosis.
Int J Tuberc Lung Dis 2007, 11:1282–1289.
10. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S,
Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S: The immune reconstitution
inflammatory syndrome after antiretroviral therapy initiation in patients with
tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012, 157:313–324.
11. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A:
Cause-specific mortality and the contribution of immune reconstitution
inflammatory syndrome in the first 3 years after antiretroviral therapy
initiation in an urban African cohort. Clin Infect Dis 2009, 49:965–972.
12. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS,
Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U,
Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim
J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash
A, Moko E, Sawe F, Andersen J, Sanne I, et al: Timing of antiretroviral
therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011,
365:1482–1491.
13. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL,
Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G,
Abdool Karim Q: Integration of antiretroviral therapy with tuberculosis
treatment. N Engl J Med 2011, 365:1492–1501.
14. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y,
Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard
B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE, CAMELIA
(ANRS 1295–CIPRA KH001) Study Team: Earlier versus later start of
antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J
Med 2011, 365:1471–1481.
15. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S,
Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B,
Nilkamhang S, Sungkanuparph S, TIME Study Team: Time to initiate
antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis
treatment in HIV-infected patients: results from the TIME study. J Acquir
Immune Defic Syndr 2012, 60:377–383.
16. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, Su SC, Ho MW, Cheng
SH, Yang CH, Lin YH, Miao WJ, Sheng WH, Hung CC: Seroprevalence of
chronic hepatitis B virus infection among taiwanese human
immunodeficiency virus type 1-positive persons in the era of nationwide
hepatitis B vaccination. Am J Gastroenterol 2009, 104:877–884.
17. Taiwan CDC: Taiwan Tuberculosis Control Report 2012. Taiwan Centers for
Disease Control: Taipei; 2013.
18. Yang CH, Huang YF, Lin YJ, Tang JC: Analysis of Taiwan HIV/AIDS related database
between 2007 and 2011. Taiwan Centers for Disease Control: Taipei; 2011.
19. Huang YF, Chen CH, Chang FY: The emerging HIV epidemic among men
who have sex with men in Taiwan. J Formos Med Assoc 2013,
112:369–371.
20. Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, Hung CC, Yang SY: Trends
of mortality and causes of death among HIV-infected patients in Taiwan,
1984-2005. HIV Med 2008, 9:535–543.
21. Lo HY, Yang SL, Chou P, Chuang JH, Chiang CY: Completeness and
timeliness of tuberculosis notification in Taiwan. BMC Public Health 2011,
11:915.
22. Taiwan CDC: Guidelines for diagnosis and Treatment of HIV/AIDS, 2nd edition
edn. Taiwan Centers for Disease Control: Taipei; 2008.
23. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C,
Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK: Causes of death
in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009,
15:258–264.
24. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, Marais E,
McIntyre J, Chaisson RE, Hale M: Causes of death in hospitalized adults with a
premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007,
21:2043–2050.
Yang et al. BMC Infectious Diseases 2014, 14:304 Page 9 of 10
http://www.biomedcentral.com/1471-2334/14/304
25. Kung HC, Sun HY, Chen MY, Hsieh SM, Sheng WH, Chen YC, Hung CC, Chang SC:
Human immunodeficiency virus testing among patients with tuberculosis at
a university hospital in Taiwan, 2000 to 2006. J Formos Med Assoc 2009,
108:320–327.
26. Yang CH, Yang SY, Shen MH, Kuo HS: The changing epidemiology of
prevalent diagnosed HIV infections in Taiwan, 1984-2005. Int J Drug
Policy 2008, 19:317–323.
27. Gadkowski LB, Hamilton CD, Allen M, Fortenberry ER, Luffman J, Zeringue E, Stout
JE: HIV-specific health care utilization and mortality among tuberculosis/HIV
coinfected persons. AIDS Patient Care STDS 2009, 23:845–851.
28. Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R: Delays in starting
antiretroviral therapy in patients with HIV-associated tuberculosis accessing
non-integrated clinical services in a South African township. BMC Infect Dis
2011, 11:258.
29. WHO: Antiretroviral therapy for HIV infection in adults and adolescents:
Recommendations for a public health approach(2010 revision) 2010.
30. Kendon MA, Knight S, Ross A, Giddy J: Timing of antiretroviral therapy
initiation in adults with HIV-associated tuberculosis: outcomes of therapy
in an urban hospital in KwaZulu-Natal. S Afr Med J 2012, 102:931–935.
31. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK,
Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT: Early versus delayed
initiation of antiretroviral therapy for Indian HIV-Infected individuals with tu-
berculosis on antituberculosis treatment. BMC Infect Dis 2012, 12:168.
32. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA,
Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J, Adult AIDS
Clinical Trials Group A5221 Study Team: Tuberculosis immune
reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity
and implications for HIV-TB programs. J Acquir Immune Defic Syndr 2013,
65:423–428.
33. Franke MF, Robins JM, Mugabo J, Kaigamba F, Cain LE, Fleming JG, Murray
MB: Effectiveness of early antiretroviral therapy initiation to improve
survival among HIV-infected adults with tuberculosis: a retrospective
cohort study. PLoS Med 2011, 8:e1001029.
34. Chilton D, Edwards SG, Pellegrino P, Miller RF: Factors influencing delay in
initiating antiretroviral therapy among HIV infected patients coinfected
with tuberculosis. Thorax 2008, 63:935–936.
35. Pukenyte E, Lescure FX, Rey D, Rabaud C, Hoen B, Chavanet P, Laiskonis AP,
Schmit JL, May T, Mouton Y, Yazdanpanah Y: Incidence of and risk factors
for severe liver toxicity in HIV-infected patients on anti-tuberculosis
treatment. Int J Tuberc Lung Dis 2007, 11:78–84.
36. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J,
Swaden L, Johnson MA, Cropley I, Lipman MC: Adverse events and
treatment interruption in tuberculosis patients with and without HIV
co-infection. Thorax 2006, 61:791–794.
37. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH,
Yang PC: Risk factors of hepatitis during anti-tuberculous treatment and
implications of hepatitis virus load. J Infect 2011, 62:448–455.
38. Sun HY, Chen YJ, Gau CS, Chang SC, Luh KT: A prospective study of
hepatitis during antituberculous treatment in Taiwanese patients and a
review of the literature. J Formos Med Assoc 2009, 108:102–111.
39. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, Yamuah L,
Feleke B, Aseffa A: Anti-tuberculosis therapy-induced hepatotoxicity among
Ethiopian HIV-positive and negative patients. PLoS One 2008, 3:e1809.
40. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of
serious side effects from first-line antituberculosis drugs among patients
treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167:1472–1477.
doi:10.1186/1471-2334-14-304
Cite this article as: Yang et al.: The impact of HAART initiation timing on
HIV-TB co-infected patients, a retrospective cohort study. BMC Infectious
Diseases 2014 14:304.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yang et al. BMC Infectious Diseases 2014, 14:304 Page 10 of 10
http://www.biomedcentral.com/1471-2334/14/304
